Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,035
archived clinical trials in
Bipolar Disorder

Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Charleston, SC
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Charleston, SC
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Memphis, TN
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Memphis, TN
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Austin, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Austin, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Dallas, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
DeSoto, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
DeSoto, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Houston, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Houston, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Wharton, TX
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Wharton, TX
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Charlottesville, VA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Bothell, WA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Bothell, WA
Click here to add this to my saved trials
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated:  11/14/2012
Clinical Research Facility
mi
from
Kirkland, WA
Extension Study of Asenapine {P06107 (NCT01244815)} for Pediatric Bipolar Disorder (P05898 AM3)
A 50-Week Open-Label, Flexible-Dose Trial of Asenapine Extension Treatment to P06107 in Pediatric Acute Manic or Mixed Episodes Associated With Bipolar I Disorder (Protocol No. P05898)
Status: Enrolling
Updated: 11/14/2012
Clinical Research Facility
mi
from
Kirkland, WA
Click here to add this to my saved trials
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated:  12/10/2012
Emory University School of Medicine: Wesley Woods Health Center
mi
from
Atlanta, GA
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated: 12/10/2012
Emory University School of Medicine: Wesley Woods Health Center
mi
from
Atlanta, GA
Click here to add this to my saved trials
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated:  12/10/2012
Tufts Medical Center
mi
from
Boston, MA
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated: 12/10/2012
Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated:  12/10/2012
Duke University School of Medicine
mi
from
Durham, NC
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Treatment for Bipolar Depression: Acute & Prophylactic Efficacy With Citalopram
Status: Enrolling
Updated: 12/10/2012
Duke University School of Medicine
mi
from
Durham, NC
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
Childrens National Medical Center
mi
from
Washington,
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
Childrens National Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
University of Illinois at Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
University of Kansas School of Medicine
mi
from
Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, KA
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
University of Kansas School of Medicine
mi
from
Psychiatry and Behavioral Sciences, 1010 N Kansas St, Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
Univ of Massachusetts Med School
mi
from
Worcester, MA
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
Univ of Massachusetts Med School
mi
from
Worcester, MA
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
Columbia University
mi
from
New York, NY
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
Cincinnati Childrens Hospital Medical Center
mi
from
Cincinnati, OH
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
Cincinnati Childrens Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
University of Cincinnati
mi
from
Cincinnati, OH
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
University Hospitals of Cleveland
mi
from
Cleveland, OH
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated:  12/14/2012
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Safety and Efficacy Study of Lithium for the Treatment of Pediatric Mania.
A Randomized, Double-blind, Placebo Controlled Study of the Efficacy of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long-term Safety Period, Double-blind, Placebo-controlled Discontinuation Phase, and Open Label Restabilization Period.
Status: Enrolling
Updated: 12/14/2012
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated:  12/21/2012
Clinical Research Facility
mi
from
Miami, FL
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated: 12/21/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated:  12/21/2012
Clinical Research Facility
mi
from
Lansing, MI
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated: 12/21/2012
Clinical Research Facility
mi
from
Lansing, MI
Click here to add this to my saved trials
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated:  12/21/2012
Clinical Research Facility
mi
from
Kansas City, MO
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated: 12/21/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated:  12/21/2012
Clinical Research Facility
mi
from
Seattle, WA
Study in Adolescents With Schizophrenia or Bipolar Disorder
A Long-Term, Open-Label, Safety Study of Oral Olanzapine in Adolescents With Bipolar I Disorder (Manic or Mixed Episodes) or Schizophrenia
Status: Enrolling
Updated: 12/21/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Asenapine in the Treatment of Older Adults With Bipolar Disorder
Asenapine in the Treatment of Older Adults With Bipolar Disorder
Status: Enrolling
Updated:  1/14/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Asenapine in the Treatment of Older Adults With Bipolar Disorder
Asenapine in the Treatment of Older Adults With Bipolar Disorder
Status: Enrolling
Updated: 1/14/2013
University Hospitals of Cleveland
mi
from
Cleveland, OH
Click here to add this to my saved trials
Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder
Decision Making and Mental Health: Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder
Status: Enrolling
Updated:  2/25/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder
Decision Making and Mental Health: Cognitive De-Biasing and the Assessment of Pediatric Bipolar Disorder
Status: Enrolling
Updated: 2/25/2013
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance
A Randomized, Double-Blind, Placebo-Controlled Study of Add-On Ramelteon in Ambulatory Bipolar I Disorder With Clinically Significant Sleep Disturbance
Status: Enrolling
Updated:  5/8/2013
Lindner Center of HOPE
mi
from
Mason, OH
Add-On Ramelteon in Bipolar I Disorder With Clinically Significant Sleep Disturbance
A Randomized, Double-Blind, Placebo-Controlled Study of Add-On Ramelteon in Ambulatory Bipolar I Disorder With Clinically Significant Sleep Disturbance
Status: Enrolling
Updated: 5/8/2013
Lindner Center of HOPE
mi
from
Mason, OH
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Woodland International Research Group, Inc.
mi
from
Little Rock, AR
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Clinical Innovations, Inc
mi
from
Costa Mesa, CA
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Clinical Innovations, Inc
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Collaborative Neuroscience Network
mi
from
Garden Grove, CA
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Compass Research North, LLC
mi
from
Leesburg, FL
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Compass Research North, LLC
mi
from
Leesburg, FL
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Advanced Pharma CR, LLC
mi
from
Miami, FL
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Advanced Pharma CR, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated:  9/19/2013
New Hope Clinical Research
mi
from
Charlotte, NC
Bio-equivalence Study Between SAPHRIS and Asenapine
An Open-label, Randomized, Two Treatment, Multi-site, Multiple Dose, Steady State, Three-way, Reference-replicated Crossover, Pharmacokinetic Study to Determine the In-vivo Bioequivalence Between Asenapine 10 mg Sublingual Tablet and SAPHRIS® (Asenapine) 10 mg Sublingual Tablet
Status: Enrolling
Updated: 9/19/2013
New Hope Clinical Research
mi
from
Charlotte, NC
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Johns Hopkins University
mi
from
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
University of Maryland
mi
from
Baltimore, MD
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
The Zucker Hillside Hospital
mi
from
Glen Oaks, NY
Click here to add this to my saved trials
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated:  12/17/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
An Open-Label Pilot Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents
Status: Enrolling
Updated: 12/17/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Status: Enrolling
Updated:  1/24/2014
University of Pittsburgh
mi
from
Pittsburgh, PA
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Status: Enrolling
Updated: 1/24/2014
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Status: Enrolling
Updated:  1/24/2014
University of Pittsburgh, Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Light Therapy for Bipolar Disorder. Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Efficacy of Light Therapy for Bipolar Depression: A Randomized Controlled Trial
Status: Enrolling
Updated: 1/24/2014
University of Pittsburgh, Western Psychiatric Institute and Clinic
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Springdale, AK
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Springdale, AK
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Little Rock, AR
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated:  4/22/2014
Clinical Research Facility
mi
from
Cerritos, CA
Long-Term Safety Extension Trial of Asenapine in Bipolar 1 Disorder Participants Who Completed Protocol P05691 (P05692)
A Multicenter, Double-Blind, Fixed-Dose, Long-Term Extension Trial of the Safety of Asenapine in Subjects Diagnosed With Bipolar 1 Disorder Who Completed Protocol P05691 (Formerly 041044) (Phase3B, Protocol P05692 [Formerly 041045])
Status: Enrolling
Updated: 4/22/2014
Clinical Research Facility
mi
from
Cerritos, CA
Click here to add this to my saved trials